Responses
Clinical/translational cancer immunotherapy
Original research
Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T
Compose a Response to This Article
Other responses
No responses have been published for this article.